NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Forecast, Price & News $12.05 +0.11 (+0.92%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$11.80▼$12.4050-Day Range$6.94▼$13.8552-Week Range$4.61▼$14.34Volume519,300 shsAverage Volume466,027 shsMarket Capitalization$524.66 millionP/E Ratio5.29Dividend YieldN/APrice Target$16.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Voyager Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside32.8% Upside$16.00 Price TargetShort InterestHealthy3.20% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.57Based on 6 Articles This WeekInsider TradingSelling Shares$147,684 Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.01 to ($1.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.72 out of 5 starsMedical Sector73rd out of 1,010 stocksBiological Products, Except Diagnostic Industry10th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Voyager Therapeutics has a forecasted upside of 32.8% from its current price of $12.05.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.20% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 77.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.59. Previous Next 3.1 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Voyager Therapeutics this week, compared to 4 articles on an average week.Search Interest10 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows4 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,684.00 in company stock.Percentage Held by Insiders22.00% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.58% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from $1.01 to ($1.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 5.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 5.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.77.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 7.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Voyager Therapeutics (NASDAQ:VYGR) StockVoyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.Read More Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Stock News HeadlinesMay 27, 2023 | msn.comNewshub, Lisette Reymer, Karen Rutherford win at 2023 Voyager Media AwardsMay 27, 2023 | msn.comRNZ takes home several top Voyager Media AwardsMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 25, 2023 | msn.comOcean Voyager cruise ship visits EscanabaMay 25, 2023 | finance.yahoo.comVoyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?May 23, 2023 | msn.comLower Cape Fear LifeCare hosting Camp Voyager to help grieving childrenMay 20, 2023 | thestreet.comEmbattled Crypto Broker Voyager to Return $1.3 Billion to CustomersMay 18, 2023 | finance.yahoo.comVoyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual MeetingMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 18, 2023 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) vs. Mosaic ImmunoEngineering (OTCMKTS:CPMV) Head to Head SurveyMay 17, 2023 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) versus Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head ComparisonMay 13, 2023 | americanbankingnews.comAnalysts Offer Predictions for Voyager Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VYGR)May 12, 2023 | msn.comCanaccord Genuity Maintains Voyager Therapeutics (VYGR) Buy RecommendationMay 12, 2023 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Upgraded to Buy at StockNews.comMay 12, 2023 | americanbankingnews.comWedbush Weighs in on Voyager Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:VYGR)May 11, 2023 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Now Covered by Truist FinancialMay 9, 2023 | finance.yahoo.comVoyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass EstimatesMay 8, 2023 | msn.comVoyager Therapeutics Q1 2023 Earnings PreviewMay 8, 2023 | msn.comEarnings Preview For Voyager TherapeuticsMay 7, 2023 | americanbankingnews.comVoyager Therapeutics (VYGR) to Release Quarterly Earnings on TuesdayMay 6, 2023 | msn.comHow The Voyager Spacecraft Are Still Running After More Than 40 YearsMay 5, 2023 | news.yahoo.comNASA Hack Squeezes More Time Out of Dying Voyager 2 ProbeMay 5, 2023 | finance.yahoo.comRevenues Working Against Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Share PriceMay 4, 2023 | finance.yahoo.comVoyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?May 2, 2023 | finance.yahoo.comVoyager Therapeutics Announces First Quarter 2023 Conference Call and WebcastApril 28, 2023 | msn.comVoyager 2 has been in space for 45 years. NASA just found a way to keep it alive for another 3, despite it being 12 billion miles from Earth.April 28, 2023 | msn.comNew power plan will keep Voyager 2 running even longerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Company Calendar Last Earnings3/07/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$18.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+32.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$2.28 Trailing P/E Ratio5.29 Forward P/E Ratio11.93 P/E GrowthN/ANet Income$-46,410,000.00 Net Margins-24.21% Pretax Margin52.26% Return on Equity95.18% Return on Assets45.67% Debt Debt-to-Equity RatioN/A Current Ratio15.18 Quick Ratio15.18 Sales & Book Value Annual Sales$40.91 million Price / Sales12.82 Cash FlowN/A Price / Cash FlowN/A Book Value$4.98 per share Price / Book2.42Miscellaneous Outstanding Shares43,540,000Free Float33,958,000Market Cap$524.66 million OptionableOptionable Beta1.12 Key ExecutivesAlfred W. SandrockPresident, Chief Executive Officer & DirectorRobin SwartzChief Operating OfficerPeter P. PfreundschuhChief Financial & Accounting OfficerTodd CarterChief Scientific OfficerJulie BurekVice President-FinanceKey CompetitorsOmega TherapeuticsNASDAQ:OMGAAgenusNASDAQ:AGENAmbrx BiopharmaNYSE:AMAMAutolus TherapeuticsNASDAQ:AUTLiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 37,946 shares on 5/18/2023Ownership: 0.826%Armistice Capital LLCBought 128,000 shares on 5/16/2023Ownership: 8.094%Gilder Gagnon Howe & Co. LLCBought 27,463 shares on 5/16/2023Ownership: 0.222%State Street CorpBought 5,300 shares on 5/16/2023Ownership: 0.216%Squarepoint Ops LLCBought 43,201 shares on 5/16/2023Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions VYGR Stock - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price forecast for 2023? 2 brokers have issued 1-year target prices for Voyager Therapeutics' shares. Their VYGR share price forecasts range from $14.00 to $18.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 32.8% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2023? Voyager Therapeutics' stock was trading at $6.10 at the beginning of 2023. Since then, VYGR stock has increased by 97.5% and is now trading at $12.05. View the best growth stocks for 2023 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its earnings results on Tuesday, March, 7th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.04. The company earned ($1.55) million during the quarter, compared to analysts' expectations of $12.71 million. Voyager Therapeutics had a positive trailing twelve-month return on equity of 95.18% and a negative net margin of 24.21%. What ETFs hold Voyager Therapeutics' stock? ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (8.85%), Armistice Capital LLC (8.09%), Price T Rowe Associates Inc. MD (2.07%), BlackRock Inc. (1.89%), Farallon Capital Management LLC (1.83%) and Acadian Asset Management LLC (1.71%). Insiders that own company stock include Alfred Sandrock, Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $12.05. How much money does Voyager Therapeutics make? Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $524.66 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.28 on an earnings per share basis. How many employees does Voyager Therapeutics have? The company employs 101 workers across the globe. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com. This page (NASDAQ:VYGR) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.